Viva Biotech Holdings (VBIZF)
OTCMKTS · Delayed Price · Currency is USD
0.3434
+0.1526 (79.98%)
At close: Jan 26, 2026
Viva Biotech Holdings Employees
Viva Biotech Holdings had 2,085 employees as of June 30, 2025. The number of employees increased by 22 or 1.07% since the number was reported on December 31, 2024.
Employees
2,085
Change
22
Growth
1.07%
Revenue / Employee
$122,967
Profits / Employee
$11,535
Market Cap
637.07M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 2,085 | 22 | 1.07% |
| Dec 31, 2024 | 2,063 | -14 | -0.67% |
| Dec 31, 2023 | 2,077 | -524 | -20.15% |
| Dec 31, 2022 | 2,601 | 474 | 22.28% |
| Dec 31, 2021 | 2,127 | 508 | 31.38% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Viva Biotech Holdings News
- 6 weeks ago - Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities - PRNewsWire
- 2 months ago - Sobi To Acquire Arthrosi Therapeutics - Nasdaq
- 2 months ago - Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. - PRNewsWire
- 4 months ago - Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry - PRNewsWire
- 5 months ago - Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights - PRNewsWire
- 6 months ago - Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth - PRNewsWire
- 11 months ago - Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection - PRNewsWire
- 11 months ago - Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D - PRNewsWire